How to Test for Drug Allergies: Types of Tests

Drug allergy testing relies on a combination of skin-based tests, blood tests, and controlled drug challenges, with the right approach depending on whether your reaction was immediate (within an hour of taking the drug) or delayed (days later). No single test catches every type of drug allergy, and the accuracy of each method varies dramatically depending on which drug triggered your reaction. The whole process often begins with something deceptively simple: a detailed account of what happened the last time you took the medication in question.

Why the Type of Reaction Determines the Test

Drug allergy reactions broadly fall into two camps. Immediate reactions happen within minutes to an hour after taking a drug and involve the immune system producing IgE antibodies. These can range from hives and swelling to full-blown anaphylaxis. Delayed reactions show up hours to weeks later and involve different immune cells. These can manifest as rashes, blistering skin conditions, or serious multi-organ syndromes. The distinction matters because the tests used for immediate reactions are largely useless for delayed ones, and vice versa.

Your allergist will typically classify your reaction based on your history before selecting which tests to run. A person who broke out in hives ten minutes after swallowing amoxicillin is on a very different diagnostic track than someone who developed a widespread rash a week into a course of the same antibiotic. The clinical features of the reaction and the specific drug involved both influence which test has the best chance of giving a meaningful answer.¹

Skin Prick Testing

The skin prick test is the most familiar allergy test. A tiny amount of the suspected drug is placed on your forearm or back, and the skin is lightly pricked through the droplet. If you are sensitized to that drug through an IgE-mediated pathway, a small raised bump (a wheal) appears within about 15 to 20 minutes. A wheal of 3 mm or larger in diameter, compared to a negative saline control, counts as a positive result.²

Skin prick tests work well for screening immediate allergies to most drug classes, with one notable exception: opioids tend to cause direct skin irritation that looks like a positive result even in people who are not truly allergic. For this reason, opioid skin prick tests are generally avoided or interpreted with extra caution.¹

The test is quick, inexpensive, and carries very little risk of triggering a serious reaction. Its main limitation is sensitivity: a negative skin prick test does not necessarily mean you are safe to take the drug, especially with certain drug classes. That is where intradermal testing comes in.

Intradermal Testing

Intradermal testing takes things a step further. Instead of placing the drug on the skin surface, a small amount of diluted drug solution is injected just under the skin using a fine needle, similar to a tuberculosis skin test. This method is more sensitive than a prick test because it introduces the drug directly to the immune cells in the skin.

Intradermal tests appear to be particularly useful for detecting immediate allergies to beta-lactam antibiotics (the family that includes penicillin and amoxicillin), iodinated contrast dyes used in CT scans, heparins, general anesthetics, and platinum-based chemotherapy drugs.¹ For rituximab, a biologic used in cancer and autoimmune disease treatment, intradermal testing with a specific concentration showed a positive predictive value of 100% for immediate hypersensitivity in one study, meaning every positive test correctly identified someone who would react. The negative predictive value was roughly 85%, meaning a small percentage of people with negative tests still reacted.³

Because the drug goes deeper into the skin, intradermal testing carries a slightly higher risk of triggering a systemic reaction than a prick test. It is performed under medical supervision, with resuscitation equipment at hand. Intradermal tests can also be read at a delayed time point (48 to 72 hours later) to catch delayed-type reactions, making them versatile tools in drug allergy workups.

For some delayed reactions, delayed-reading intradermal tests may actually outperform patch testing. In conditions like drug rash with eosinophilia and systemic symptoms (DRESS) and maculopapular rashes, delayed intradermal testing tends to be more sensitive than patch testing.⁴

Patch Testing for Delayed Reactions

Patch testing is the workhorse for delayed drug allergies, especially the severe kind. Small discs containing the suspected drug are taped to your back and left in place for 48 hours, then read at 48 and sometimes 96 hours. A positive result shows redness, swelling, or tiny blisters at the test site, indicating that your immune cells recognize and react to the drug.

Patch testing has proven especially valuable in DRESS, a serious delayed reaction that involves fever, rash, and organ inflammation. In a systematic review of nearly 300 DRESS patients, patch testing was the most commonly used test (used in over 97% of cases), and about 58% of those tests came back positive.⁵ That might sound modest, but these are notoriously difficult reactions to pin down, and a positive test can be decisive in identifying the culprit drug.

The sensitivity of patch testing depends heavily on the drug. Anticonvulsants, particularly carbamazepine, produce the highest rate of positive patch tests in DRESS, followed by beta-lactam antibiotics like amoxicillin, and antituberculosis agents. In contrast, some drugs that commonly cause DRESS, such as allopurinol and sulfasalazine, essentially never produce a positive patch test.⁶ This is a real blind spot: if your allergist suspects allopurinol caused your DRESS, a negative patch test does not help much.

Patch testing in DRESS also has a practical role beyond identifying the original offender. After a DRESS episode, some patients develop sensitivities to multiple structurally unrelated drugs. Patch testing can map out which drugs are safe and which are not, and it can reveal cross-reactivities that were not obvious from the clinical history. About 18% of DRESS patients tested in one series showed this kind of multisensitization on patch testing.⁷

When Patch Testing Gets Dangerous

For the most severe delayed skin reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), testing decisions become more cautious. Intradermal testing is generally considered too risky because it can provoke the original reaction. Patch testing can be performed in SJS/TEN, though its diagnostic yield tends to be low.⁴ In a systematic review of patch testing in SJS/TEN patients, about 4% experienced mild systemic reactions during testing, though these only required conservative management.⁸ The decision about whether to patch test after SJS/TEN is made on a case-by-case basis, weighing the clinical need to identify the culprit drug against a small but real risk of flaring symptoms.

Blood Tests and Laboratory-Based Approaches

When skin testing is impractical, unavailable, or risky, blood tests offer an alternative. For immediate-type allergies, a serum-specific IgE test can detect antibodies against certain drugs circulating in your blood. This is essentially the same concept as a skin prick test, just done in a lab instead of on your skin. It avoids any risk of triggering a reaction, but standardized IgE tests are only available for a handful of drugs, and their sensitivity is generally lower than skin testing.

Two more specialized blood tests have been gaining ground in allergy clinics, though they remain less widely available than skin tests.

The basophil activation test (BAT) measures how your basophils, a type of white blood cell involved in allergic reactions, respond when exposed to the suspected drug in a test tube. One study found the BAT had a sensitivity of about 98% and specificity of 96% for drug allergies, with strong predictive values in both directions.⁹ Those numbers are impressive, though they come from a specialized center. The BAT is not yet standardized or widely available in routine practice, and results can vary between laboratories. It is most often used when skin testing is inconclusive or cannot be performed safely.

The lymphocyte transformation test (LTT) is aimed at delayed reactions. It works by incubating your blood cells with the suspected drug and measuring whether your lymphocytes proliferate in response. Unlike the BAT, which targets immediate reactions, the LTT is better suited for delayed hypersensitivity syndromes. It appears to have higher sensitivity for DRESS than for other delayed reaction types, and timing matters: testing done very early (within two weeks of the reaction) seems to yield more reliable results than testing done later.¹⁰ In hospitalized patients who developed skin reactions during COVID-19 treatment, the LTT successfully identified candidate culprit drugs in cases where drug challenge was not feasible.¹¹

Tryptase Levels During Acute Reactions

If you are evaluated during or shortly after an acute allergic reaction to a drug, your doctor may draw blood for tryptase, an enzyme released by mast cells during anaphylaxis. Tryptase is not a test you schedule in advance; it is a snapshot taken in the moment to help confirm whether a reaction involved systemic mast cell activation. Comparing an acute tryptase level (drawn during or just after the reaction) to a baseline level (drawn once you have recovered) can help distinguish a true IgE-mediated anaphylactic event from other types of immediate reactions that might look similar but involve different mechanisms.¹²

Paired tryptase measurements can also flag underlying conditions like mastocytosis or hereditary alpha-tryptasemia, which make a person more prone to severe allergic reactions. Identifying these conditions changes how aggressively the allergy is managed going forward.

Drug Provocation Testing

Drug provocation testing, sometimes called a drug challenge, is the closest thing to a gold standard in drug allergy diagnosis. Under medical supervision, you are given the suspected drug in gradually increasing doses while being monitored for a reaction. If you tolerate the full therapeutic dose, you are almost certainly not allergic, and the allergy label can be removed from your medical record.

For penicillin, the most commonly mislabeled drug allergy, provocation testing has been shown to be remarkably safe in people screened as low risk. In a study of just over 1,000 adults who underwent direct drug provocation without prior skin testing, none had a serious reaction. Ten patients (1%) experienced mild immediate symptoms, and only one of those was thought to be a genuine IgE-mediated allergic response.¹³ The study excluded people with a history of anaphylaxis within the past five years or a severe delayed reaction, which is an important caveat: provocation testing is not for everyone.

For children with histories of delayed, non-severe reactions to amoxicillin, a two-step oral challenge protocol (two doses 30 minutes apart, then continued for five days) has also been used as a direct testing approach, sometimes without prior skin testing.¹⁴ The logic here is that many childhood “allergies” to amoxicillin were actually viral rashes that coincided with antibiotic use. Proving tolerance early means the child does not carry a false allergy label into adulthood.

Risk Stratification Before Testing

Not every patient with a penicillin allergy label needs the full battery of skin testing and provocation. Structured risk-assessment tools can help sort people into categories. The PEN-FAST tool, for example, uses a short questionnaire about the features of the original reaction to estimate the likelihood of a truly positive skin test. In one study applying PEN-FAST in an outpatient setting, half of patients scored as low to very low risk for a positive penicillin skin test, and a third scored as moderate risk.¹⁵ Low-risk patients may be appropriate candidates for direct provocation without skin testing, while higher-risk patients proceed through the full stepwise workup. Tools like these are increasingly used in delabeling programs that aim to clear inaccurate allergy labels from medical charts.

Cross-Reactivity Testing

One of the most useful applications of drug allergy testing is figuring out which related drugs are safe when you are allergic to one member of a drug family. This comes up constantly with antibiotics. If you are allergic to penicillin, can you take a cephalosporin? The answer depends on the chemical structures involved, and testing can sort it out.

In an Australian study of patients with confirmed cephalosporin allergies, skin testing and oral challenges revealed that cross-reactivity patterns followed the chemical side-chain structures of the drugs. The majority (about 88%) of cephalosporin-allergic patients who also carried a penicillin allergy label actually tolerated penicillin on challenge and had their penicillin allergy removed. However, about 10% of patients with confirmed cefazolin allergy who had never been labeled as penicillin-allergic turned out to have positive penicillin skin tests, an unexpected finding that highlights why systematic cross-reactivity testing matters.¹⁶

Testing for Biologics and Chemotherapy Drugs

Allergies to biologic medications and chemotherapy agents present a different challenge. These drugs are often irreplaceable for a given patient, so the goal of testing is less about avoidance and more about guiding desensitization, a procedure where the drug is given in very small, gradually increasing amounts to temporarily induce tolerance.

Skin testing helps decide whether desensitization is needed and which protocol to use. With rituximab, for instance, skin tests were performed in patients who had reactions, and the results (positive or negative, along with the clinical history) guided the choice among different desensitization protocols.¹⁷ Some patients who initially tested negative converted to positive on repeat testing, illustrating that sensitivity can develop over time with repeated drug exposures.

When the Drug Is Not the Problem

Sometimes the allergic reaction is not to the active drug at all, but to an inactive ingredient, an excipient. Polyethylene glycol (PEG), found in laxatives, injectable medications, and some vaccines, is a well-documented trigger of anaphylaxis in rare cases. In the largest case series at the time of publication, four of five confirmed PEG-allergic patients had experienced anaphylaxis to PEG-containing medications, including one near-fatal episode. Diagnosis required skin prick and intradermal testing with PEG solutions of different molecular weights, and in one case an oral challenge, because standard drug allergy panels would miss this entirely.¹⁸

This kind of allergy is worth knowing about because PEG is everywhere: in cosmetics, processed foods, and hundreds of pharmaceutical products.¹⁹ If you have had unexplained allergic reactions to seemingly unrelated medications, an excipient allergy is something your allergist should consider.

Why Removing False Allergy Labels Matters

A large proportion of people labeled as drug-allergic, particularly to penicillin, are not truly allergic. The consequences of carrying a false label are more serious than most people realize. Unconfirmed penicillin allergy labels are strongly linked to inappropriate use of broader-spectrum antibiotics, which contributes to the growing problem of antibiotic-resistant infections. Delabeling, the process of formally removing an inaccurate allergy from a patient’s chart after testing, allows patients to receive first-line antibiotics and reduces healthcare costs.²⁰

Delabeling programs have been gaining momentum worldwide, using combinations of risk stratification, skin testing, and provocation challenges to systematically work through patients carrying allergy labels. These programs sit at the intersection of allergy and antimicrobial stewardship, and they represent one of the clearest examples of how drug allergy testing translates directly into better population-level health outcomes.

Drug Allergy Testing in Children

Children pose a particular diagnostic puzzle. Drug hypersensitivity studies have largely focused on adults, and diagnostic tools have been validated in relatively few pediatric patients. Guidelines for testing children generally follow adult protocols, but the context is different: many childhood “drug allergies” are misattributed viral rashes, and the stakes of carrying a false label from age five onward are considerable because it shapes antibiotic choices across a lifetime of infections.²¹

Non-IgE-mediated reactions are especially poorly understood in pediatrics. The mechanisms behind many delayed rashes in children are not well defined, and there are no validated diagnostic markers for most of them. The result is that many children end up with permanent drug restrictions based on a single ambiguous episode, relying on second-line drugs that may be less effective and more expensive.²² This is an area where the gap between what we can test for and what we need to test for is widest.

Putting the Testing Sequence Together

In practice, drug allergy testing rarely involves a single test in isolation. The typical workup follows a stepwise approach that starts with the least risky procedure and escalates only if needed. For suspected immediate allergies, the sequence usually goes: skin prick test first, then intradermal test if the prick test is negative, and then a graded drug provocation if both skin tests are negative and the clinical need for the drug is strong. For delayed reactions, the sequence might start with patch testing or delayed-reading intradermal tests, potentially supplemented by a lymphocyte transformation test when those are inconclusive, and again potentially culminating in a provocation challenge under controlled conditions.

The entire process is shaped by a risk-benefit calculation that is unique to each patient. Someone who had a mild rash from amoxicillin years ago and now needs it for an infection has a very different risk profile than someone who landed in the ICU with anaphylaxis from the same drug last month. The testing pathway adjusts accordingly, with lower-risk patients sometimes skipping straight to provocation and higher-risk patients proceeding more cautiously through each layer of testing. What matters most is that the process ends with a clear answer, either confirming the allergy and documenting safe alternatives, or removing the label and restoring access to the drug.

1
PubMed. Skin Testing Approaches for Immediate and Delayed Hypersensitivity Reactions
2
PubMed Central. The skin prick test – European standards
3
PubMed Central. Use of Skin Testing Screening and Desensitization Before the First Exposure of Rituximab
4
Annals of Allergy, Asthma & Immunology. How to Test for Drug Allergies: Types of Tests – Section: Skin Testing for Delayed Reactions
5
PubMed. Utility and Safety of Skin Tests in Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): A Systematic Review
6
PubMed. Patch testing in drug reaction with eosinophilia and systemic symptoms (DRESS): A literature review
7
The Journal of Allergy and Clinical Immunology: In Practice. Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs – Section: Drug Reaction with Eosinophilia and Systemic Symptoms
8
PubMed. Drug patch testing in Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review
9
PubMed Central. Real-Life Utility of Basophil Activation Test in the Diagnosis of Immediate Hypersensitivity Drug Reactions
10
PubMed. Lymphocyte transformation test for drug allergy detection: When does it work?
11
PubMed Central. Value of the Lymphocyte Transformation Test for the Diagnosis of Drug-Induced Hypersensitivity Reactions in Hospitalized Patients with Severe COVID-19
12
PubMed. Tryptase in drug-induced anaphylaxis: the need for acute and baseline values
13
PubMed. Safety of Direct Drug Provocation for the Evaluation of Penicillin Allergy in Low-Risk Adults
14
PubMed Central. Safety of direct oral provocation testing using the Amoxicillin-2-step-challenge in children with history of non-immediate reactions to amoxicillin
15
PubMed Central. Describing Self-Reported Penicillin Allergy Using a Penicillin Allergy Risk Tool (PEN-FAST) in an Outpatient Setting at a Tertiary Hospital in Saudi Arabia
16
PubMed Central. Cephalosporin allergy: R1 side-chain and penicillin cross-reactivity patterns in an Australian cohort
17
PubMed. Rituximab Hypersensitivity: Evaluation, Desensitization, and Potential Mechanisms
18
PubMed. Polyethylene Glycol-Induced Systemic Allergic Reactions (Anaphylaxis)
19
PubMed Central. Hypersensitivity to polyethylene glycol in adults and children: An emerging challenge
20
The Korean Journal of Medicine. Drug Allergy Delabeling
21
PubMed Central. Drug Allergy in Children: What Should We Know?
22
PubMed Central. Non-IgE-mediated drug-induced hypersensitivity reactions in pediatrics